Innoviva, Inc. — 2011 Q3 Form 10-Q Summary
Filing identity: The supplied 10-Q identifies the registrant as Theravance, Inc., not Innoviva, Inc. It covers the unaudited quarter and nine months ended September 30, 2011; confirm the issuer and filing before relying on this summary.
Business context and reporting period
Theravance was a clinical-stage biopharmaceutical company developing medicines in respiratory disease, bacterial infections, and CNS/pain, with major programs partnered with GlaxoSmithKline (GSK) and telavancin partnered with Astellas. The interim financial statements are unaudited and prepared under U.S. GAAP; management cautioned that interim results are not necessarily indicative of full-year results.
Financial results and position
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $6.4 million | $5.3 million | $19.2 million | $17.3 million |
| Research and development expense | $27.8 million | $18.5 million | $71.1 million | $57.6 million |
| General and administrative expense | $7.8 million | $6.6 million | $22.2 million | $20.1 million |
| Operating loss | $29.2 million | $19.8 million | $74.2 million | $60.4 million |
| Net loss | $30.6 million | $21.2 million | $78.3 million | $64.6 million |
| Basic and diluted loss per share | $0.37 | $0.29 | $0.96 | $0.91 |
- Revenue and margins: Revenue increased 21% for the quarter and 11% year to date. The filing attributes the increases mainly to higher VIBATIV royalties and, in the year-to-date comparison, the absence of a $0.8 million charge for unrealizable VIBATIV inventory recorded in 2010. Operating losses widened as spending rose faster than revenue. The filing does not provide a clear gross-margin measure.
- Cash flow: For the first nine months, operating cash use was $63.0 million, versus $60.1 million in 2010; investing cash use was $60.4 million, versus $22.3 million; financing provided $22.8 million, versus $97.9 million. Cash and cash equivalents fell $100.6 million to $62.7 million. Investing outflows mainly reflect purchases of short-term securities, not solely operating expenditure.
- Liquidity: Cash, cash equivalents, and marketable securities totaled $265.2 million at September 30, 2011, down $44.5 million from year-end 2010. Management said this was sufficient for anticipated operating needs for at least the next 12 months under current plans and assumptions. Restricted cash of $0.9 million was excluded from that total.
- Debt and balance sheet: The company had $172.5 million of unsecured 3.0% convertible subordinated notes due January 15, 2015; estimated fair value was $183.2 million. Total assets were $283.3 million, and stockholders’ net capital deficiency was $59.2 million. The accumulated deficit was $1.279 billion.
- Equity financing: Net proceeds from common-stock issuances were $22.9 million for the nine months, including $12.3 million from private placements with a GSK affiliate. Shares outstanding rose to 85.1 million from 71.0 million at year-end 2010.
Material changes versus the prior comparable period
- Quarterly and year-to-date net losses increased by $9.4 million and $13.8 million, respectively, primarily amid higher R&D costs. R&D expense rose 50% in Q3 and 23% year to date, driven mainly by external clinical-development costs, including PμMA and MARIN activities, and higher employee-related costs.
- G&A expense increased 18% in Q3 and 10% year to date, mainly due to employee-related expenses.
- VIBATIV royalties rose to $0.8 million for Q3 and $2.1 million year to date, compared with $0.4 million and $0.5 million, respectively, in 2010. Cumulative VIBATIV net sales reported by Astellas through September 30, 2011 were $22.5 million.
- The company received a $3.0 million GSK milestone for starting a Phase 1 MABA combination study. In October 2011, after quarter-end, it expanded the MABA collaboration to six additional preclinical compounds, received a $1.0 million upfront payment, and regained rights to the MARIN and ARNI programs as GSK relinquished its options on them.
Outlook, management commentary, and key risks
- Management expected R&D expense for the remainder of 2011 to increase relative to the first three quarters; G&A was expected to remain at a similar level. The filing provides no numerical revenue or earnings guidance.
- RELOVAIR Phase 3 programs were described as on track, with COPD results anticipated early in 2012 and asthma results in the first half of 2012. The ‘719/VI Phase 3 program and ‘081 MABA Phase 2b program were also described as progressing in line with expectations. TD-1211 PμMA Phase 2b enrollment was progressing.
- VIBATIV received European Commission authorization in September 2011 for specified cases of hospital-acquired pneumonia caused or suspected to be caused by MRSA when other alternatives are unsuitable; European launch plans were under review. The U.S. telavancin pneumonia application remained unresolved: FDA feedback indicated additional studies would be required, and the company said it did not plan to conduct them, while continuing discussions with FDA.
- Material risks include clinical-trial failure or delay, changing FDA requirements—particularly for LABAs in asthma—dependence on GSK and Astellas, and the possibility that Astellas could terminate the telavancin agreement. VIBATIV also faced single-source supply risks: the drug-product supplier had cGMP deficiencies identified by regulators and announced plans to exit contract manufacturing over several years; the filing said no EU-specification drug product had yet been manufactured.
- Potential future obligations include up to $220 million of milestone payments to GSK if specified VI products are launched in multiple regions. The company also disclosed $45.5 million of future minimum operating lease payments. No significant changes in contractual obligations were reported for the first nine months.
- Special performance-based retention awards could produce substantial future compensation expense if targets are achieved; as of September 30, 2011, management considered achievement not probable and recorded no expense for those awards. The filing also states disclosure controls were effective and reports no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm that this Theravance, Inc. 2011 filing is the intended issuer and period for the Innoviva request.
- Check subsequent results and regulatory outcomes for RELOVAIR, ‘719/VI, MABA, and TD-1211 against the development timelines described.
- Verify VIBATIV sales, royalty trends, EU launch status, Astellas’s continuing commitment, and resolution of the manufacturing and cGMP issues.
- Assess cash burn and financing needs against the stated 12-month liquidity outlook, including the $172.5 million note maturity in 2015 and potential GSK milestones.
- Review dilution from equity issuance, GSK’s ownership and governance rights, and the potential expense and vesting conditions of performance-based awards.